Donate

Where Have I been the Past Week?

Over this past week I have not been able to make any post to the blog. I apologize to anybody kept coming back to the blog and didn't see anything new. Two Sunday nights ago I was admitted to the hospital and had an emergency appendectomy the following Tuesday night. Due to my age and [...]

Thank You My Readers for Your Support in Being Awarded the Harry Pinchot Service Award

I recently was informed that I am to honored with the 2014 Harry Pinchot Award from the Prostate Cancer Research Institute.  The award recognizes outstanding dedication and support to the prostate cancer community. I am pleased and flattered to be one of this year's receptients.I have been told that one reason I have received this [...]

Excessive Alcohol Consumption May Lead to Increased Cancer Risk

The question: Can heavy alcohol consumption accelerate telomere shortening & does telomere shortening cause premature aging and an increased cancer risk? Many of us like to drink alcoholic beverages. I confess, I too enjoy red wind have been known to enjoy a single malt scotch on occasion. However, we always need to remember that excessive [...]

Sodium Clodronate Improves Survival In Patients With Advanced Prostate Cancer But Not With Localized Disease

An article published Online First and in an upcoming edition of The Lancet Oncology reports that an oral bisphosphonate, sodium clodronate, improves overall survival in men with advanced prostate cancer. However, it does not reduce the risk of death in men with localized disease. These are the final results of the MRC PR05 and MRC [...]

Neuroendocrine Prostate Cancer – A Tough Disease To Treat

We are finding that there are many different types of prostate cancer, all of them are actually different diseases. At Memorial Sloane Kettering Hospital, New York City, they recently announced that, based on genetic analysis, they have identified 23 different types of prostate cancer. One of these cancer types is neuroendocrine prostate cancer which is [...]

A New Clinical Trial of MDV3100 in Earlier Advanced Prostate Cancer

— A New Trial Marks Expanded Phase 3 Development of MDV3100 into Earlier-Stage Disease — Medivation, Inc. and Astellas Pharma Inc. today announced the launch of a second Phase 3 clinical trial of their investigational drug MDV3100.  This trial marks the expansion of the Phase 3 development of their novel, triple-acting oral androgen receptor antagonist [...]

On the Horizon- Custirsen for Men with Advanced Prostate Cancer

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced the publication of results from their randomized Phase 2 trial of custirsen for men with advanced prostate cancer in the September 20, 2010 Journal of Clinical Oncology. According to their announcement, the trial results showed a survival benefit with their investigational agent OGX-011/TV1011 (custirsen) in men with advanced prostate [...]

Leukine – A Second Line Hormone Therapy (Part 3 of a Series of Posts on Second Line Hormone Therapy)

Leukine, a granulocyte macrophage colony-stimulating factor (GM-CSF), is a hormone therapy that does not have an effect on a man’s testosterone production. Leukine is used by many physicians who are knowledgeable about the value of second line hormone therapy. Leukine works by stimulating the white blood cells (both increasing the overall production of the white [...]

Estrogen – A Second Line Hormone Therapy (Part 2 of a Series of Posts on Second Line Hormone Therapy)

One of the earliest hormone therapies (ADT) given to men to treat prostate cancer was estrogen. Estrogen, commonly known as the female hormone, was used as an ADT treatment in the early 1950s. […]

Go to Top